VIVUS Inc. (VVUS)

3.21
NASDAQ : Health Technology
Prev Close 3.44
Day Low/High 3.21 / 3.48
52 Wk Low/High 2.15 / 6.60
Avg Volume 22.80K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 36.61M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Lessons From 2013 J.P. Morgan Healthcare Confab

Biotech Stock Lessons From 2013 J.P. Morgan Healthcare Confab

The best and worst biotech and drug companies to emerge from last week's investor conference.

Orexigen Obesity Pill Catching Up With Competitors

Orexigen Obesity Pill Catching Up With Competitors

While behind Vivus and Arena Pharma, Orexigen's market value is lower.

Vivus Stock Falls On Unusually High Volume (VVUS)

Vivus Stock Falls On Unusually High Volume (VVUS)

Vivus (Nasdaq:VVUS) is trading at unusually high volume Tuesday with 9.8 million shares changing hands. It is currently at two times its average daily volume and trading down 49 cents (-3.3%).

Arena Pharmaceuticals And 6 More Stocks To Watch

Arena Pharmaceuticals And 6 More Stocks To Watch

Rising short-interest indicates bearishness for the company is building up by investors. Between November 30 2012 and December 14, short-selling [...]

7 Stocks Soaring on Unusual Volume

7 Stocks Soaring on Unusual Volume

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

Live, interactive coverage of the biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

Vivus (VVUS): Today's Featured Health Care Laggard

Vivus (VVUS): Today's Featured Health Care Laggard

Vivus was a leading decliner within the health care sector, falling 25 cents (-2.3%) to $10.54 on average volume.

Vivus (VVUS): Today's Featured Health Care Laggard

Vivus (VVUS): Today's Featured Health Care Laggard

Vivus was a leading decliner within the health care sector, falling 25 cents (-2.3%) to $10.54 on average volume.

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

Nate Sadeghi's 2012 Biotech Stock Report Card

Nate Sadeghi's 2012 Biotech Stock Report Card

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

Vivus (VVUS): Today's Featured Drugs Laggard

Vivus (VVUS): Today's Featured Drugs Laggard

Vivus was a leading decliner within the drugs industry, falling 30 cents (-2.6%) to $11.43 on light volume.

8 Stocks Climbing Higher on Unusual Volume

8 Stocks Climbing Higher on Unusual Volume

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

5 Stocks Pushing The Health Care Sector Higher

5 Stocks Pushing The Health Care Sector Higher

TheStreet Ratings group would like to highlight 5 stocks pushing the health care sector higher today, Nov. 21, 2012.

Vivus, Arena Rise on New Insurance Coverage For Obesity Pills

Vivus, Arena Rise on New Insurance Coverage For Obesity Pills

Aetna will now cover Qsymia and Belviq as medically neccessary medications for weight loss.

'Mad Money' Lightning Round: Sell, Sell, Sell Vivus and Frontier

'Mad Money' Lightning Round: Sell, Sell, Sell Vivus and Frontier

Buy buy buy Boardwalk Partners, Cramer said, but stay away from JC Peney and Sears.

Cramer's 'Mad Money' Recap: Panicking Brokers

Cramer's 'Mad Money' Recap: Panicking Brokers

The election result and the continuing economic problems in the U.S. and Europe have brokers urging investors to sell, which they did in droves, Cramer said.

Cramer's 6 Stocks in 60 Seconds: WPRT HII COF SBAC VVUS X (Update1)

Cramer's 6 Stocks in 60 Seconds: WPRT HII COF SBAC VVUS X (Update1)

Steer clear of Capital One, Westport Innovations and Huntington Ingalls, Cramer said, but he's bullish on SBA Communications.

Arena Pharma Sinks Under Weight Of Vivus' Troubles

Arena Pharma Sinks Under Weight Of Vivus' Troubles

The weight-loss pill market is not the blockbuster opportunity once envisioned.

Vivus Weight-Loss Drug Launch In Early Trouble (Updated)

Vivus Weight-Loss Drug Launch In Early Trouble (Updated)

Lackluster sales, reimbursement issues hamper sales of Vivus' Qsymia.

4 Stocks Rising On Unusual Volume

4 Stocks Rising On Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Arena Pharma Is Still A Good Short

Arena Pharma Is Still A Good Short

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

21 Most Volatile Biopharma Stocks Closing Out 2012

21 Most Volatile Biopharma Stocks Closing Out 2012

These biopharma firms will be announcing FDA drug approval decisions and important clinical trial results.

The Next Big Thing in Biotech

The Next Big Thing in Biotech

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

Vivus Weight-Loss Drug's Failing Math

Vivus Weight-Loss Drug's Failing Math

The launch of Vivus' obesity pill Qsymia has been disappointing to date.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet columnist Adam Feuerstein takes your biotech investing questions.

Biotech Stock Mailbag: Ziopharm, Sarepta, Vivus, Aegerion, Gilead

Biotech Stock Mailbag: Ziopharm, Sarepta, Vivus, Aegerion, Gilead

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

7 Stocks Rising on Big Volume

7 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

TheStreet Quant Rating: D (Sell)